Genomic profiling of lethal primary PCa tumors reported TP53 alterations in 27% of samples, whereas in RPE samples from intermediate- or high-risk disease TP53 mutations were present in 18% [47,48] (Figure 3). Here, TP53 is linked to posterior cortical atrophy.